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Quality of bronchoscopy performed by one single pulmonologist in a scarcely populated subarctic area was compared to the
guidelines provided by the British Thoracic Society (BTS). 103 patients underwent bronchoscopy. Diagnostic yield was increased
to 76.6% when the ﬁrst bronchoscopy was supplemented by bronchial washing ﬂuid and brush cytology and to 86.7% (BTS
guidelines >80%) after a second bronchoscopy. Median time from referral to bronchoscopy was 10 days and 8 days from positive
bronchoscopy to operative referral to another hospital. 1% of patients that underwent transbronchial lung biopsy had minor
complications.Onepulmonologisthadrateofcorrectdiagnosisbasedonvisibleendobronchialtumorsthatwascomparabletothe
rates of numerous pulmonologists at larger centers performing the same procedure. Time delay was short. Rate of complications
was comparable. Bronchoscopy performed by one pulmonologist alone could, in organized settings, be carried out at local
hospitals in areas of scattered settlement.
1.Introduction
The British Thoracic Society (BTS) has given guidelines for
bronchoscopy and diagnostic yield when performing bron-
choscopy of visible potentially malignant lesions [1]. The
guidelines are based on the practice of large bronchoscopy-
performing facilities. With 16 inhabitants per square kilome-
ter, Norway is, following Iceland, the least densely populated
country in Europe. In our subarctic county the density is
mere 5pr·km2. We wanted to investigate whether broncho-
scopic procedures performed by the only pulmonologist at a
small local hospital in this county could match the demands
of the British guidelines. We have mapped out the time spent
from the onset of symptoms to referral, assessment, exami-
nation (bronchoscopy), operation, and further clariﬁcation
at another hospital. The aim of this study was to see if the
pulmonologist in question (R. Berntsen) had a diagnostic
yield in percent exceeding 80, which is the limit of the BTS
guidelines, and, simultaneously, if the number of complica-
tions was at an acceptable level.
2.MaterialsandMethods
The survey comprises 119 patients indicated for bron-
choscopy in a nine-year period ending in 2006. Deidentiﬁed
information concerninggender,age,smoking, relevant times
of bronchoscopy, indication for bronchoscopy, type of local
anesthetic used, and types of complications was gathered
from the patient’s journal and from a separate patient pro-
tocol and written out by the same nurse in pulmonology
during the entire period. The pulmonologist plotted the
information into an Excel spreadsheet and analyzed it by the
means of autoﬁlter functions and pivot tables.
Two nurses, of whom one specialized in pulmonology,
assisted the pulmonologist during the procedure. In case of
emergency an anesthetist would also be of assistance. Pa-
tients with all kinds of bleeding diatheses did not under-
go bronchoscopy, and anticoagulants would have to be post-
poned in advance if biopsies were planned. Patients were
also screened upfront by a wide panel of blood tests, ECG,
spirometry, pulse oximetry. Patients with asthma would2 Pulmonary Medicine
Table 1: Description of the 103 patients who underwent broncho-
scopy.
Women Men
Number 40 63
Median age (distribution) 69 (34–82) 66 (23–89)
Fraction smokers 29/40 58/63
Second bronchoscopy 1 5
Table 2: Reason of referral.
Women Men
Hemoptysis 10 13
Suspected malignancy 23 41
Lung consolidation without suspected malignancy 6 6
Other 1 3
receive salbutamol inhalation before bronchoscopy. COPD
patients with bronchial hyperreactivity who responded to
bronchodilators would get salbutamol and ipratropium bro-
mide before bronchoscopy. One hour after bronchoscopy
with transbronchial biopsies, chest X-ray was taken to ex-
clude pneumothorax.
T h ep r o c e d u r ew a sc a r r i e do u tw i t haﬂ e x i b l eb r o n c h o -
scope. All the patients were premedicated with Hydrocodone
tablets 5–10mg and 0.6mg subcutaneous injections of
Atropine. Patients with asthma or bronchial hyperreactivity
were additionally given Ventoline and Atrovent on a vapor-
izer. All patients were administered xylocaine locally in the
throat/larynx and received an additional Xylocaine spray
oncethevocalcordsweretransited.Nonewasinitiallyoﬀered
intravenous midazolam but three were either administered
diazepam or midazolam during the procedure. 90% of the
patients were policlinical.
3. Results
Sixteen (13%) of the 119 patients that were referred did not
have a bronchoscopy, even though eight had an indication
for it. Tables 1, 2, 3, 4 and 5 show the characteristics of the
103 patients that underwent bronchoscopy, their reason for
referral, timeline, complications, and diagnoses. The results
of the bronchoscopy and the ensuing diagnostic course are
illustrated in Figure 1.
4. Discussion
4.1. Reason for Referral/Diagnosis. A diagnostic yield of
86.7% is in accord with the BTS guidelines [1]. The guide-
lines recommend biopsy, brush cytology, and bronchial
washing ﬂuid when a lesion is visible by bronchoscopy. In
their guidelines, BTS cites a study of 5 centers that perform
bronchoscopy with a diagnostic yield of malignancy by biop-
sy at 82% [1]. Combined use of bronchial washing ﬂuid
and brush cytology increased this yield to 87% when bron-
choscopy revealed visible lesions with a malignant appear-
ance. In our study, malignancy at ﬁrst bronchoscopy was
Table 3: Time spent.
Period No. of
patients
Days median
(25–75 percentile)
From symptoms to hospital referral 78 68 (30–150)
From referral to bronchoscopy 103 10 (6–25)
From bronchoscopy to surgical
referral 10 8 (7–11)
From surgical referral to surgery 8 33 (27–44)
From bronchoscopy to further
elaboration and treatment 30 10 (6–14)
From bronchoscopy to further
elaboration and treatment in
another hospital
29 38 (27–58)
Table 4: Complications to the 103 bronchoscopies.
Transbronchial
N = 13
Non-transbronchial
N = 90
None 10 89
Minor, not life-threatening(1) 2 (15%) 1 (1,1%)
Serious(2) (pneumothorax
with drain) 1( 8 % ) 0
(1) BTS deﬁnition [1]: Vasovagal reaction, fever, arrhythmia, bleeds, airway
obstruction, pneumothorax without the need of drain, nausea, vomiting.
(2) BTS deﬁnition [1]: Respiratory depression, pneumonia, pneumothorax
in need of chest drain tube, airway obstruction, cardiorespiratory arrest, ar-
rhythmia, pulmonary edema.
Table 5: Diagnostic method for ﬁnal diagnosis in the 53 cases of
malignant pulmonary disease and other malignancy.
n %
Initial bronchoscopy 30 56,6
Second bronchoscopy 7 13,2
Transthoracic CT guided biopsy 6 11,3
Mediastinoscopy 3 5,6
Operation, open lung biopsy 3 5,6
detected in 56.6% of the cases, in contrast to 44.9% in other
studies [2].
In our material, the diagnostic yield of malignancy was
9% when the lesions were endoscopically invisible. This is
equal to a Scottish study where the yield was at 9% [3].
Of the patients diagnosed with primary lung cancer by
the pulmonologist, 31% (nine patients) were operable. Of
these nine, one did not wish to have the operation. In
comparison, use of surgery in patients with NSCLC in a UK
region was 13% [4]. The reason for such a high number
of operable patients in our material is possibly due to the
short period from hospital referral to the performed bron-
choscopy, but we cannot exclude this as a coincidence or due
to other variables.
We had a relatively large fraction of patients undergoing
bronchoscopy by indication of hemoptysis without proven
pulmonic alterations by diagnostic imaging. Only one of
these patients was diagnosed with malignancy. This is well
in accord with textbooks in pulmonology [5].Pulmonary Medicine 3
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Figure 1
Our hospital conducts few bronchoscopies per annum
but its advantage shown in this study is that the same doctor
performs nearly all these. The same doctor (R. Berntsen)
carried out all but one of the bronchoscopies in our material.
Larger facilities perform a greater amount of bronchoscopies
but the number is divided between a larger work force of
whom some at all times are under training. Also in Norway
pulmonologists are generally well educated in the procedure
of bronchoscopy before doing it on their own, and suﬃcient
time to do bronchoscopy is allocated. The pulmonologist in
this study also had fewer competing tasks as few patients
receive mechanical ventilation in this small hospital.4 Pulmonary Medicine
4.2. Time Consumption. Our study proved that there was a
short delay—a median of 10 days—fromthe hospital referral
to the actual bronchoscopy, and 8 days from bronchoscopy
to operative referral to another hospital. These delays are in
accordance with BTS recommendations to respiratory physi-
cians for organising the care of patients with lung cancer [6].
Itislikelytobelieve,buthardtoprove,thataprolongedperi-
od of diagnosing and treating lung cancer aggravates the
prognosis [7].
4.3.Complications. IntheBTSguidelinesitisstatedthatﬂex-
ible bronchoscopy is an extremely safe procedure if the basic
precautions are taken [1]. Three retrospective studies are
cited. One reports a mortality of 0.01% and serious compli-
cations in 0.08% of 24521 procedures. Another states 0.02%
mortality and 0.3% serious complications in approximately
48000 procedures. The third study reports 0.04% mortality
and0.12%seriouscomplicationsinabout40000procedures.
A smaller prospective study of 4000 procedures, including
2000 with bronchoalveolar lavage and 173 transbronchial
biopsies, revealed a higher rate of complications with 0.5%
and 0.8% serious and minor complications, respectively.
There were no deaths. It is further pointed out that the risk
of complications (pneumothorax in 1–5% of cases and light
b l e e d si n9 %o fc a s e s )w a sh i g h e rw h e nat r a n s b r o n c h i a l
biopsy was taken. The serious life-threatening complica-
tions mentioned in the BTS guidelines include respirato-
ry depression, pneumonia, pneumothorax in need of a chest
drain tube, airway obstruction, cardiorespiratory failure,
arrhythmia, and pulmonary edema. Lesser, not life-threaten-
ing complications, include in declining frequency, vasovagal
reactions, fever, cardiac arrhythmias, bleeds, airway obstruc-
tion, pneumothorax without need of drain tube, nausea, and
vomiting.
In our study minor, non-life-threatening complications
arose in 1% of cases and no serious complications of the pro-
cedure when transbronchial lung biopsy (TBB) was not per-
formed. This is well in accord with the BTS guidelines. With
TBB the rate of minor complications (bronchospasm and
pneumothorax) was greater than 15%, whereas the rate for
serious complications (pneumothorax in need of drain tube)
was 8%. To reduce the risk of complications from ﬂexible
bronchoscopy, the BTS guidelines advise to avoid routinely
atropine as premedication. The atropine is administered to
reduce the bronchial secretion and suppress vagal hyperac-
tivity. Atropine use is largely based on traditional anesthetic
practice preceding rigid bronchoscopy. A study revealed that
patients receiving atropine as premedication had less need
of lidocaine as a local anesthetic, but there were no other
apparent advantages. Premedication with anticholinergic
agents may also dissolve bronchoconstriction induced by
local anesthetics. This is of potential value to asthmatic pa-
tients. Atropine may cause tachycardia and can be proar-
rhythmogenic, cause blurry vision, trigger glaucoma, and
dryness of the mouth. In our material there were no patients
that presented with any of these side eﬀects of atropine yet it
is prudent to consider the BTS guidelines. Our study shows
that after a thorough education by skilled pulmonologists in
larger hospitals, one single pulmonologist in a small hospital
can safely perform bronchoscopy by carefully selecting the
patients.
4.4. Nonexamined Patients. The group was not clearly dis-
tinguishable from the group that underwent bronchoscopy.
16 patients were not examined. Four had an interrupted
procedure because of panic attacks and laryngospasms, three
had contraindications to the procedure, one was excluded
based on a negative CT following an initially positive chest
X-ray,inonecasethediagnosiswasmadefromaliverbiopsy,
one procedure was cancelled because of a faulty scope-
cleaning apparatus, and one was excluded when the initially
suspectedmalignantinﬁltrateprovedtobebenign.Theseven
patients with a solid indication for bronchoscopy could most
likely have completed the procedure if they had been oﬀered
sedation in addition to local anesthetics, and this is now the
standard. The BTS guidelines recommend that all patients
should be oﬀered sedation if there is no contraindication.
Midazolam, propofol, or the combination of benzodiazepine
and short-acting opiate, like alfentanil, is recommended. It is
important to realize that Norway demands anesthesiologist
be present when a patient receives medication causing loss of
consciousness.
5. Conclusions
We found one pulmonologist to have rate of correct diag-
nosis, based on visible endobronchial tumors, comparable
to the rates of numerous pulmonologists at larger centers
performing the same procedure. This was also true con-
cerning the time spent and the complications encountered.
Bronchoscopyperformedbyonepulmonologistalonecould,
inorganizedsettings,becarriedoutatlocalhospitalsinareas
of scattered settlement.
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